In this article:

Metastasis Disappears in First Patient Treated with New Russian Cancer Vaccine

The first patient treated with Russia's personalized mRNA cancer vaccine has achieved complete remission with no signs of metastasis for roughly four months, according to the Gamaleya Research Center.
Imagen
NeoOncovac

NeoOncovac, la vacuna rusa contra el melanoma. Foto: Telegram @nmicr

Author:

The first patient to receive the new personalized Russian cancer vaccine has been in complete remission for about four months, announced Alexander Gintsburg, scientific director of Moscow's Gamaleya National Research Center for Epidemiology and Microbiology, in an interview with Gazeta.ru.

The latest medical examinations have revealed no new tumor formations, and the metastasis the patient previously presented has disappeared, he confirmed.

The Russian vaccine uses messenger RNA (mRNA) technology and is developed individually for each patient, taking into account the genetic profile of their tumor. Its goal is to train the immune system to recognize the specific characteristics of cancer cells so it can identify and destroy them.

Despite the promising initial results, the patient will remain under medical supervision for the next three years. This follow-up will allow doctors to verify the stability of the remission, monitor for possible relapses, and evaluate the body's long-term response to the treatment.

According to Gintsburg, a total of six patients have already received the vaccine. The second patient is halfway through the 10-injection course and is tolerating it better than the first, without even developing a mild fever. By the end of the year, doctors expect to treat 20 patients. "We have everything needed for it," he assured.

Progress in Cancer Vaccine Development

The personalized vaccine NeoOncovac, designed to treat melanoma, was jointly developed by the Gamaleya Center and the Blokhin National Medical Research Center of Oncology. Russian citizens can receive it free of charge through mandatory health insurance, which covers virtually the entire population.

In addition to NeoOncovac, Russia is currently developing:

  • Peptide vaccines: based on synthetic analogs of tumor antigens, which stimulate the immune system to attack cancer cells. One example is Oncopept, for the treatment of colorectal cancer.

  • Oncolytic virus-based vaccines: using modified viruses that selectively infect and destroy malignant cells. One example is EnteroMix.

The National Medical Research Radiological Center of the Russian Ministry of Health noted that artificial intelligence is helping identify mutations in the human genome to create drugs that combat tumors.

Add new comment

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.